ArticleClinical ophthalmology (Auckland, N.Z.)2025
Early Adoption and Utilization of Perfluorohexyloctane for Dry Eye Disease in the United States.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To characterize early adopters of perfluorohexyloctane (PFHO) and 90-day refill rates after the first prescription, overall and compared to a cohort initiating cyclosporine ophthalmic emulsion 0.05% (CsA). Patients and Methods: Patients ≥18 years newly initiating PFHO or CsA between September and November 2023 were identified in IQVIA open-source medical and pharmacy claims databases (date of first claim = index date). Demographics, index prescription characteristics, 12-month baseline clinical characteristics, and 90-day refill rates were descriptively compared between cohorts. A multivariable logistic regression model was developed to evaluate factors associated with the adjusted odds of 90-day refill of the respective index therapy. Results: The final sample included 7,209 PFHO and 75,871 CsA patients (mean age: 60.6 and 66.6 years; 79.9% and 80.4% female; 67.0% and 39.4% third party payer; respectively). In total, 75.9% of PFHO patients received their prescription through the mail while 92.2% of CsA patients received it through the retail setting. Only 38.5% of PFHO and 33.3% of CsA patients had a diagnosis of dry eye disease (DED) over the 12-month baseline period. Nearly half (46.6%) of PFHO patients used at least one different DED medication over the 12-month baseline compared to 8.1% of CsA patients. Over the 90-day follow-up, most (72.0%) PFHO patients refilled the prescription for their index therapy compared to 37.4% of CsA patients. In the multivariable logistic regression model, PFHO patients had 72% higher likelihood of refilling their index prescription within 90-days compared to CsA patients (adjusted odds ratio: 1.72; 95% confidence interval: 1.60-1.86). Conclusion: High DED medication use among PFHO patients in the 12-month period prior to treatment initiation suggests that prior medication may not have resolved their DED symptoms. The higher 90-day refill rate for PFHO versus CsA indicates a higher degree of patient satisfaction with this new, first-in-class treatment for DED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.